Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec 06, 2014	MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting Results Show Durable Responses in High Risk Patient Population	View HTML MorphoSys and Xencor Publish Final Results from Phase 1/2a Trial of MOR208 (XmAb5574) in CLL/SLL at ASH Annual Meeting 25 KB
Toggle SummaryDec 04, 2014	Xencor to Present at the 25th Annual Oppenheimer & Co. Healthcare Conference MONROVIA, Calif. , Dec. 4, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at the 25th Annual Oppenheimer & Co. Healthcare Conference 15.4 KB
Toggle SummaryNov 25, 2014	Xencor to Present at the 2014 Deutsche Bank BioFEST Conference MONROVIA, Calif. , Nov. 25, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at the 2014 Deutsche Bank BioFEST Conference 13.8 KB
Toggle SummaryNov 10, 2014	Xencor Reports Third Quarter 2014 Financial Results Conference call today at 4:30 p.m. EST	View HTML Xencor Reports Third Quarter 2014 Financial Results 30.2 KB
Toggle SummaryNov 06, 2014	Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting Multiple T-cell engaging bispecific programs show potential as disease modifying treatments for acute myelogenous leukemia, B-cell lymphomas and leukemia, and multiple myeloma Xencor designates its first bispecific antibody candidate, XmAb14045 an anti-CD123xCD3, for IND-enabling studies MONROVIA,	View HTML Xencor Provides Data Updates on XmAb Bispecific Antibody Programs and Announces Presentations at Upcoming American Society of Hematology 2014 Annual Meeting 19.5 KB
Toggle SummaryNov 04, 2014	Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference MONROVIA, Calif. , Nov. 4, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat , Ph.D.,	View HTML Xencor to Present at the 2014 Credit Suisse Annual Healthcare Conference 12.7 KB
Toggle SummaryNov 03, 2014	Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call MONROVIA, Calif. , Nov. 3, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release third quarter	View HTML Xencor to Host Third Quarter 2014 Financial Results Webcast and Conference Call 12.7 KB
Toggle SummaryOct 28, 2014	Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) Ongoing Phase 1b/2a clinical trial on track to report topline results by end of 2014 Conference call today at 5:00 p.m. EDT MONROVIA, Calif. , Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc.	View HTML Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease 68.8 KB
Toggle SummarySep 02, 2014	Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel MONROVIA, Calif. , Sept. 2, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Debra Zack ,	View HTML Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 16 KB
Toggle SummaryAug 05, 2014	Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference MONROVIA, Calif. , Aug. 5, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that John Desjarlais , Ph.D.,	View HTML Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference 12.8 KB

Tools

Press Releases